Attached files
| file | filename |
|---|---|
| EX-99.2 - EX-99.2 - Evofem Biosciences, Inc. | d521123dex992.htm |
| EX-99.1 - EX-99.1 - Evofem Biosciences, Inc. | d521123dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
(Amendment No. 3)
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
January 17, 2018
EVOFEM BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-36754 | 20-8527075 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
12400 High Bluff Drive, Suite 600
San Diego, CA 92130
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including area code
(858) 550-1900
Not applicable.
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Explanatory Note
The sole purpose of this amendment to our Current Report on Form 8-K/A, originally filed with the Securities and Exchange Commission on March 1, 2018 (the “Form 8-K/A”), is to furnish Exhibits 101 to the Form 8-K/A, which contain the XBRL (eXtensible Business Reporting Language) Interactive Data File for the Audited Consolidated Financial Statements of Evofem Biosciences, Inc. as of and for the years ended December 31, 2017 and 2016 included as Exhibit 99.1 in the Form 8-K/A.
No other changes have been made to the Form 8-K/A and the Form 8-K/A has not been updated to reflect events occurring subsequent to the original filing date.
Item 9.01. Exhibits.
(d) Exhibits.
Reference is made to the Exhibit Index included with this Current Report on Form 8-K.
EXHIBIT INDEX
| Exhibit No. |
Description | |
| 99.1 | Audited Consolidated Financial Statements of Evofem Biosciences, Inc. as of and for the years ended December 31, 2017 and 2016 | |
| 99.2 | Unaudited Pro Forma Condensed Consolidated Financial Statements of the Company and Evofem Biosciences Operations, Inc. as of and for the year ended December 31, 2017 | |
| 101.INS | XBRL Instance Document* | |
| 101.SCH | XBRL Taxonomy Extension Schema Document* | |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document* | |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document* | |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document* | |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document* | |
| * | Submitted electronically herewith |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| EVOFEM BIOSCIENCES, INC. | ||||||
| Date: April 6, 2018 | By: | /s/ Saundra Pelletier | ||||
| Saundra Pelletier | ||||||
| Chief Executive Officer | ||||||